A New Mechanism Of Immune Regulation That Limits The Efficacy Of Immunotherapy
Share This:
                           

About The Author

I co-direct the Ludwig Collaborative Laboratory and the Swim Across America Laboratory at Memorial Sloan Kettering. I also lead the biorepository for the Melanoma and Immunotherapeutics Service at MSK.

My research projects focus on investigating the means for developing immune-based therapies to treat cancer. In addition, some of my work aims to study the pathogenesis and treatment of melanoma and is directed in part at developing tools to study melanoma and immune responses in multiple cancers. My projects are heavily collaborative in nature, within the Wolchok lab and across different disciplines at MSK.

                       

A New Mechanism Of Immune Regulation That Limits The Efficacy Of Immunotherapy

Immunotherapy with checkpoint blockade has revolutionized cancer treatment in the last decade. With the initial FDA approval of CTLA-4 blockade with ipilimumab in 2011 followed by the first FDA approval of PD-1 blockade with pembrolizumab in 2014, these drugs have been incorporated into the standard treatment armamentarium of many different types of cancer. These antibody therapeutics, which release the CTLA-4 and PD-1 molecular brakes on immune cells so that they can more potently respond to cancer, have shown long-lasting clinical...

Read more